Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

ZEN003694 Combined with Talazoparib for the Treatment of Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Trial Status: active

This phase II trial tests whether ZEN003694 combined with talazoparib works in treating patients with ovarian, fallopian tube, or primary peritoneal cancer that has responded to platinum-based chemotherapy but has come back (recurrent platinum-sensitive). ZEN003694 may stop the growth of tumor cells by blocking proteins called BET that are needed for cell growth. Talazoparib is a PARP inhibitor. PARP is a protein that helps repair damaged deoxyribonucleic acid (DNA). Blocking PARP may prevent tumor cells from repairing their damaged DNA, causing them to die. PARP inhibitors are a type of targeted therapy. Giving ZEN003694 and talazoparib together may work better than standard chemotherapy in treating platinum-sensitive ovarian, fallopian tube, and primary peritoneal cancer.